{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:08:24Z","timestamp":1787774904505,"version":"build-2784847793"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T00:00:00Z","timestamp":1589587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T00:00:00Z","timestamp":1589587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s13679-020-00380-3","type":"journal-article","created":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T07:37:41Z","timestamp":1589614661000},"page":"165-178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":107,"title":["Deciphering the Association Between Psoriasis and Obesity: Current Evidence and Treatment Considerations"],"prefix":"10.1007","volume":"9","author":[{"given":"Kyriaki","family":"Paroutoglou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Papadavid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos Socrates","family":"Christodoulatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dalamaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,16]]},"reference":[{"key":"380_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/s0140-6736(07)61128-3","volume":"370","author":"CE Griffiths","year":"2007","unstructured":"Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263\u201371. https:\/\/doi.org\/10.1016\/s0140-6736(07)61128-3.","journal-title":"Lancet"},{"key":"380_CR2","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/s0140-6736(14)61909-7","volume":"386","author":"WH Boehncke","year":"2015","unstructured":"Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386:983\u201394. https:\/\/doi.org\/10.1016\/s0140-6736(14)61909-7.","journal-title":"Lancet"},{"key":"380_CR3","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1046\/j.1365-2230.2001.00832.x","volume":"26","author":"E Christophers","year":"2001","unstructured":"Christophers E. Psoriasis--epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26:314\u201320. https:\/\/doi.org\/10.1046\/j.1365-2230.2001.00832.x.","journal-title":"Clin Exp Dermatol"},{"key":"380_CR4","doi-asserted-by":"publisher","first-page":"e63619","DOI":"10.1371\/journal.pone.0063619","volume":"8","author":"D Hagg","year":"2013","unstructured":"Hagg D, Eriksson M, Sundstrom A, Schmitt-Egenolf M. The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. PLoS One. 2013;8:e63619. https:\/\/doi.org\/10.1371\/journal.pone.0063619.","journal-title":"PLoS One"},{"key":"380_CR5","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jaad.2009.05.047","volume":"65","author":"CC Jacobson","year":"2011","unstructured":"Jacobson CC, Kumar S, Kimball AB. Latitude and psoriasis prevalence. J Am Acad Dermatol. 2011;65:870\u20133. https:\/\/doi.org\/10.1016\/j.jaad.2009.05.047.","journal-title":"J Am Acad Dermatol"},{"key":"380_CR6","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/j.1600-0625.2007.00629.x","volume":"16","author":"R Sabat","year":"2007","unstructured":"Sabat R, Philipp S, Hoflich C, Kreutzer S, Wallace E, Asadullah K, et al. Immunopathogenesis of psoriasis. Exp Dermatol. 2007;16:779\u201398. https:\/\/doi.org\/10.1111\/j.1600-0625.2007.00629.x.","journal-title":"Exp Dermatol"},{"key":"380_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/gene.2009.11","volume":"10","author":"JT Elder","year":"2009","unstructured":"Elder JT. Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes Immun. 2009;10:201\u20139. https:\/\/doi.org\/10.1038\/gene.2009.11.","journal-title":"Genes Immun"},{"key":"380_CR8","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/jid.2009.319","volume":"130","author":"JT Elder","year":"2010","unstructured":"Elder JT, Bruce AT, Gudjonsson JE, Johnston A, Stuart PE, Tejasvi T, et al. Molecular dissection of psoriasis: integrating genetics and biology. J Invest Dermatol. 2010;130:1213\u201326. https:\/\/doi.org\/10.1038\/jid.2009.319.","journal-title":"J Invest Dermatol"},{"key":"380_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/imm.12142","volume":"141","author":"BW Kirkham","year":"2014","unstructured":"Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014;141:133\u201342. https:\/\/doi.org\/10.1111\/imm.12142.","journal-title":"Immunology"},{"key":"380_CR10","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/14656566.2019.1583207","volume":"20","author":"A Chiricozzi","year":"2019","unstructured":"Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother. 2019;20:863\u201372. https:\/\/doi.org\/10.1080\/14656566.2019.1583207.","journal-title":"Expert Opin Pharmacother"},{"key":"380_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.5314\/wjd.v2.i4.32","volume":"2","author":"M Dalamaga","year":"2013","unstructured":"Dalamaga M, Papadavid E. Metabolic co-morbidities and psoriasis: the chicken or the egg? World J Dermatol. 2013;2:32. https:\/\/doi.org\/10.5314\/wjd.v2.i4.32.","journal-title":"World J Dermatol"},{"key":"380_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5314\/wjd.v2.i4.27","volume":"2","author":"M Dalamaga","year":"2013","unstructured":"Dalamaga M. Adipocytokines and psoriasis: insights into mechanisms linking obesity and inflammation to psoriasis. World J Dermatol. 2013;2:27. https:\/\/doi.org\/10.5314\/wjd.v2.i4.27.","journal-title":"World J Dermatol"},{"key":"380_CR13","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJMra041320","volume":"352","author":"MP Schon","year":"2005","unstructured":"Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899\u2013912. https:\/\/doi.org\/10.1056\/NEJMra041320.","journal-title":"N Engl J Med"},{"key":"380_CR14","unstructured":"WHO. World psoriasis day\u2014document EB133.R2, agenda item 6.2. May 30, 2013. http:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/EB133\/B133_R2-en.pdf. Accessed January 1, 2020."},{"key":"380_CR15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","volume":"158","author":"JH Saurat","year":"2008","unstructured":"Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558\u201366. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08315.x.","journal-title":"Br J Dermatol"},{"key":"380_CR16","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/0190-9622(95)91336-x","volume":"32","author":"T Henseler","year":"1995","unstructured":"Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32:982\u20136. https:\/\/doi.org\/10.1016\/0190-9622(95)91336-x.","journal-title":"J Am Acad Dermatol"},{"key":"380_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jaad.2016.07.065","volume":"76","author":"J Takeshita","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: implications for management. J Am Acad Dermatol. 2017;76:393\u2013403. https:\/\/doi.org\/10.1016\/j.jaad.2016.07.065.","journal-title":"J Am Acad Dermatol"},{"key":"380_CR18","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s11325-017-1507-4","volume":"21","author":"E Papadavid","year":"2017","unstructured":"Papadavid E, Dalamaga M, Vlami K, Koumaki D, Gyftopoulos S, Christodoulatos GS, et al. Psoriasis is associated with risk of obstructive sleep apnea independently from metabolic parameters and other comorbidities: a large hospital-based case-control study. Sleep Breath. 2017;21:949\u201358. https:\/\/doi.org\/10.1007\/s11325-017-1507-4.","journal-title":"Sleep Breath"},{"key":"380_CR19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11325-012-0749-4","volume":"17","author":"M Dalamaga","year":"2013","unstructured":"Dalamaga M, Papadavid E, Vlami K. Unmasking the Janus face of the association between psoriasis, metabolic syndrome and obstructive sleep apnea. Sleep Breath. 2013;17:449\u201350. https:\/\/doi.org\/10.1007\/s11325-012-0749-4.","journal-title":"Sleep Breath"},{"key":"380_CR20","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/j.1468-3083.2012.04580.x","volume":"27","author":"E Papadavid","year":"2013","unstructured":"Papadavid E, Vlami K, Dalamaga M, Giatrakou S, Theodoropoulos K, Gyftopoulos S, et al. Sleep apnea as a comorbidity in obese psoriasis patients: a cross-sectional study. Do psoriasis characteristics and metabolic parameters play a role? J Eur Acad Dermatol Venereol. 2013;27:820\u20136. https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04580.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"380_CR21","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jaad.2013.06.053","volume":"69","author":"IM Miller","year":"2013","unstructured":"Miller IM, Ellervik C, Yazdanyar S, Jemec GB. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69:1014\u201324. https:\/\/doi.org\/10.1016\/j.jaad.2013.06.053.","journal-title":"J Am Acad Dermatol"},{"key":"380_CR22","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1038\/nutd.2012.26","volume":"2","author":"AW Armstrong","year":"2012","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2:e54. https:\/\/doi.org\/10.1038\/nutd.2012.26.","journal-title":"Nutr Diabetes"},{"key":"380_CR23","doi-asserted-by":"publisher","first-page":"e1002739","DOI":"10.1371\/journal.pmed.1002739","volume":"16","author":"A Budu-Aggrey","year":"2019","unstructured":"\u2022\u2022 Budu-Aggrey A, Brumpton B, Tyrrell J, Watkins S, Modalsli EH, Celis-Morales C, et al. Evidence of a causal relationship between body mass index and psoriasis: a Mendelian randomization study. PLoS Med. 2019;16:e1002739. https:\/\/doi.org\/10.1371\/journal.pmed.1002739In this Mendelian randomization study, it was shown that genetically higher BMI increases the odds of psoriasis.","journal-title":"PLoS Med"},{"key":"380_CR24","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jid.2018.11.023","volume":"139","author":"K Ogawa","year":"2019","unstructured":"Ogawa K, Stuart PE, Tsoi LC, Suzuki K, Nair RP, Mochizuki H, et al. A transethnic Mendelian randomization study identifies causality of obesity on risk of psoriasis. J Invest Dermatol. 2019;139:1397\u2013400. https:\/\/doi.org\/10.1016\/j.jid.2018.11.023.","journal-title":"J Invest Dermatol"},{"key":"380_CR25","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s10654-018-0366-z","volume":"33","author":"D Aune","year":"2018","unstructured":"\u2022\u2022 Aune D, Snekvik I, Schlesinger S, Norat T, Riboli E, Vatten LJ. Body mass index, abdominal fatness, weight gain and the risk of psoriasis: a systematic review and dose-response meta-analysis of prospective studies. Eur J Epidemiol. 2018;33:1163\u201378. https:\/\/doi.org\/10.1007\/s10654-018-0366-zIn this meta-analysis, it was shown that higher BMI, waist circumference, waist-to-hip ratio, and weight gain were associated with increased psoriasis risk.","journal-title":"Eur J Epidemiol"},{"key":"380_CR26","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/ijo.2015.64","volume":"39","author":"S Upala","year":"2015","unstructured":"Upala S, Sanguankeo A. Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis. Int J Obes. 2015;39:1197\u2013202. https:\/\/doi.org\/10.1038\/ijo.2015.64.","journal-title":"Int J Obes"},{"key":"380_CR27","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/bjd.17741","volume":"181","author":"SK Mahil","year":"2019","unstructured":"\u2022\u2022 Mahil SK, McSweeney SM, Kloczko E, McGowan B, Barker JN, Smith CH. Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A critically appraised topic. Br J Dermatol. 2019;181:946\u201353. https:\/\/doi.org\/10.1111\/bjd.17741Weight loss may improve pre-existing psoriasis and may prevent de novo psoriasis in individuals with obesity.","journal-title":"Br J Dermatol"},{"key":"380_CR28","doi-asserted-by":"publisher","first-page":"e0195123","DOI":"10.1371\/journal.pone.0195123","volume":"13","author":"S Singh","year":"2018","unstructured":"\u2022 Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ, et al. Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS One. 2018;13:e0195123. https:\/\/doi.org\/10.1371\/journal.pone.0195123Obesity is a predictor of inferior response to anti-TNF-\u03b1 agents in patients with selected immune-mediated inflammatory diseases, including psoriasis and psoriatic arthritis.","journal-title":"PLoS One"},{"key":"380_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jbspin.2018.03.007","volume":"86","author":"J Shan","year":"2019","unstructured":"Shan J, Zhang J. Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: a systematic review and meta-analysis. Joint Bone Spine. 2019;86:173\u201383. https:\/\/doi.org\/10.1016\/j.jbspin.2018.03.007.","journal-title":"Joint Bone Spine"},{"key":"380_CR30","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.17738","volume":"181","author":"A Mourad","year":"2019","unstructured":"\u2022 Mourad A, Straube S, Armijo-Olivo S, Gniadecki R. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2019;181:450\u20138. https:\/\/doi.org\/10.1111\/bjd.17738. In this meta-analysis, it was shown that obesity predicts biologic treatment discontinuation.","journal-title":"Br J Dermatol"},{"key":"380_CR31","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/ced.12171","volume":"38","author":"KJ Zhu","year":"2013","unstructured":"Zhu KJ, Zhang C, Li M, Zhu CY, Shi G, Fan YM. Leptin levels in patients with psoriasis: a meta-analysis. Clin Exp Dermatol. 2013;38:478\u201383. https:\/\/doi.org\/10.1111\/ced.12171.","journal-title":"Clin Exp Dermatol"},{"key":"380_CR32","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/1346-8138.12121","volume":"40","author":"KJ Zhu","year":"2013","unstructured":"Zhu KJ, Shi G, Zhang C, Li M, Zhu CY, Fan YM. Adiponectin levels in patients with psoriasis: a meta-analysis. J Dermatol. 2013;40:438\u201342. https:\/\/doi.org\/10.1111\/1346-8138.12121.","journal-title":"J Dermatol"},{"key":"380_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12944-015-0039-9","volume":"14","author":"H Huang","year":"2015","unstructured":"Huang H, Shen E, Tang S, Tan X, Guo X, Wang Q, et al. Increased serum resistin levels correlate with psoriasis: a meta-analysis. Lipids Health Dis. 2015;14:44. https:\/\/doi.org\/10.1186\/s12944-015-0039-9.","journal-title":"Lipids Health Dis"},{"key":"380_CR34","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.18632\/oncotarget.22260","volume":"9","author":"F Bai","year":"2018","unstructured":"\u2022 Bai F, Zheng W, Dong Y, Wang J, Garstka MA, Li R, et al. Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis. Oncotarget. 2018;9:1266\u201378. https:\/\/doi.org\/10.18632\/oncotarget.22260In this meta-analysis, serum adiponectin levels were significantly lower, whereas serum lipocalin-2, chemerin, and resistin levels were significantly higher in psoriasis patients compared with controls.","journal-title":"Oncotarget"},{"key":"380_CR35","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1159\/000481882","volume":"233","author":"A Kyriakou","year":"2017","unstructured":"Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG. Serum leptin, resistin, and adiponectin concentrations in psoriasis: a meta-analysis of observational studies. Dermatology. 2017;233:378\u201389. https:\/\/doi.org\/10.1159\/000481882.","journal-title":"Dermatology"},{"key":"380_CR36","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.16437","volume":"179","author":"A Kyriakou","year":"2018","unstructured":"Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG. Effects of treatment for psoriasis on circulating levels of leptin, adiponectin and resistin: a systematic review and meta-analysis. Br J Dermatol. 2018;179:273\u201381. https:\/\/doi.org\/10.1111\/bjd.16437.","journal-title":"Br J Dermatol"},{"key":"380_CR37","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/exd.12691","volume":"24","author":"K Kanemaru","year":"2015","unstructured":"Kanemaru K, Matsuyuki A, Nakamura Y, Fukami K. Obesity exacerbates imiquimod-induced psoriasis-like epidermal hyperplasia and interleukin-17 and interleukin-22 production in mice. Exp Dermatol. 2015;24:436\u201342. https:\/\/doi.org\/10.1111\/exd.12691.","journal-title":"Exp Dermatol"},{"key":"380_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00439-007-0448-6","volume":"123","author":"S Ebrahim","year":"2008","unstructured":"Ebrahim S, Davey SG. Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology? Hum Genet. 2008;123:15\u201333. https:\/\/doi.org\/10.1007\/s00439-007-0448-6.","journal-title":"Hum Genet"},{"key":"380_CR39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.metabol.2018.11.001","volume":"92","author":"KI Avgerinos","year":"2019","unstructured":"Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: emerging biological mechanisms and perspectives. Metabolism. 2019;92:121\u201335. https:\/\/doi.org\/10.1016\/j.metabol.2018.11.001.","journal-title":"Metabolism"},{"key":"380_CR40","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s13679-019-00359-9","volume":"8","author":"C Koliaki","year":"2019","unstructured":"Koliaki C, Liatis S, Dalamaga M, Kokkinos A. Sarcopenic obesity: epidemiologic evidence, pathophysiology, and therapeutic perspectives. Curr Obes Rep. 2019;8:458\u201371. https:\/\/doi.org\/10.1007\/s13679-019-00359-9.","journal-title":"Curr Obes Rep"},{"key":"380_CR41","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/09546634.2016.1254326","volume":"28","author":"M Galluzzo","year":"2017","unstructured":"Galluzzo M, Talamonti M, Perino F, Servoli S, Giordano D, Chimenti S, et al. Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis. J Dermatolog Treat. 2017;28:299\u2013303. https:\/\/doi.org\/10.1080\/09546634.2016.1254326.","journal-title":"J Dermatolog Treat"},{"key":"380_CR42","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1001\/jamadermatol.2013.722","volume":"149","author":"P Jensen","year":"2013","unstructured":"Jensen P, Zachariae C, Christensen R, Geiker NR, Schaadt BK, Stender S, et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol. 2013;149:795\u2013801. https:\/\/doi.org\/10.1001\/jamadermatol.2013.722.","journal-title":"JAMA Dermatol"},{"key":"380_CR43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3945\/ajcn.115.125849","volume":"104","author":"P Jensen","year":"2016","unstructured":"Jensen P, Christensen R, Zachariae C, Geiker NR, Schaadt BK, Stender S, et al. Long-term effects of weight reduction on the severity of psoriasis in a cohort derived from a randomized trial: a prospective observational follow-up study. Am J Clin Nutr. 2016;104:259\u201365. https:\/\/doi.org\/10.3945\/ajcn.115.125849.","journal-title":"Am J Clin Nutr"},{"key":"380_CR44","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1159\/000455840","volume":"232","author":"P Jensen","year":"2016","unstructured":"Jensen P, Skov L. Psoriasis and obesity. Dermatology. 2016;232:633\u20139. https:\/\/doi.org\/10.1159\/000455840.","journal-title":"Dermatology"},{"key":"380_CR45","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1080\/1744666x.2016.1201423","volume":"12","author":"A Chiricozzi","year":"2016","unstructured":"Chiricozzi A, Raimondo A, Lembo S, Fausti F, Dini V, Costanzo A, et al. Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. Expert Rev Clin Immunol. 2016;12:1299\u2013308. https:\/\/doi.org\/10.1080\/1744666x.2016.1201423.","journal-title":"Expert Rev Clin Immunol"},{"key":"380_CR46","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1126\/science.7678183","volume":"259","author":"GS Hotamisligil","year":"1993","unstructured":"Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87\u201391. https:\/\/doi.org\/10.1126\/science.7678183.","journal-title":"Science"},{"key":"380_CR47","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jaci.2005.02.023","volume":"115","author":"G Fantuzzi","year":"2005","unstructured":"Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115:911\u20139; quiz 20. https:\/\/doi.org\/10.1016\/j.jaci.2005.02.023.","journal-title":"J Allergy Clin Immunol"},{"key":"380_CR48","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/j.1365-2133.2008.08823.x","volume":"159","author":"H Takahashi","year":"2008","unstructured":"Takahashi H, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol. 2008;159:1207\u20138. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08823.x.","journal-title":"Br J Dermatol"},{"key":"380_CR49","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00403-012-1310-9","volume":"305","author":"H Takahashi","year":"2013","unstructured":"Takahashi H, Tsuji H, Honma M, Ishida-Yamamoto A, Iizuka H. Increased plasma resistin and decreased omentin levels in Japanese patients with psoriasis. Arch Dermatol Res. 2013;305:113\u20136. https:\/\/doi.org\/10.1007\/s00403-012-1310-9.","journal-title":"Arch Dermatol Res"},{"key":"380_CR50","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s13679-018-0318-7","volume":"7","author":"N Spyrou","year":"2018","unstructured":"Spyrou N, Avgerinos KI, Mantzoros CS, Dalamaga M. Classic and novel adipocytokines at the intersection of obesity and cancer: diagnostic and therapeutic strategies. Curr Obes Rep. 2018;7:260\u201375. https:\/\/doi.org\/10.1007\/s13679-018-0318-7.","journal-title":"Curr Obes Rep"},{"key":"380_CR51","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1365-2133.2008.08655.x","volume":"159","author":"A Johnston","year":"2008","unstructured":"Johnston A, Arnadottir S, Gudjonsson JE, Aphale A, Sigmarsdottir AA, Gunnarsson SI, et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol. 2008;159:342\u201350. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08655.x.","journal-title":"Br J Dermatol"},{"key":"380_CR52","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1365-2230.2012.04465.x","volume":"38","author":"H Nakajima","year":"2013","unstructured":"Nakajima H, Nakajima K, Tarutani M, Sano S. Clear association between serum levels of adipokines and T-helper 17-related cytokines in patients with psoriasis. Clin Exp Dermatol. 2013;38:66\u201370. https:\/\/doi.org\/10.1111\/j.1365-2230.2012.04465.x.","journal-title":"Clin Exp Dermatol"},{"key":"380_CR53","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00403-013-1374-1","volume":"305","author":"J Mosiewicz","year":"2013","unstructured":"Mosiewicz J, Pietrzak A, Chodorowska G, Trojnar M, Szepietowski J, Reich K, et al. Rational for statin use in psoriatic patients. Arch Dermatol Res. 2013;305:467\u201372. https:\/\/doi.org\/10.1007\/s00403-013-1374-1.","journal-title":"Arch Dermatol Res"},{"key":"380_CR54","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s10552-010-9573-y","volume":"21","author":"M Dalamaga","year":"2010","unstructured":"Dalamaga M, Crotty BH, Fargnoli J, Papadavid E, Lekka A, Triantafilli M, et al. B-cell chronic lymphocytic leukemia risk in association with serum leptin and adiponectin: a case-control study in Greece. Cancer Causes Control. 2010;21:1451\u20139. https:\/\/doi.org\/10.1007\/s10552-010-9573-y.","journal-title":"Cancer Causes Control"},{"key":"380_CR55","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1515\/hmbci-2015-0016","volume":"23","author":"M Dalamaga","year":"2015","unstructured":"Dalamaga M, Christodoulatos GS. Adiponectin as a biomarker linking obesity and adiposopathy to hematologic malignancies. Horm Mol Biol Clin Invest. 2015;23:5\u201320. https:\/\/doi.org\/10.1515\/hmbci-2015-0016.","journal-title":"Horm Mol Biol Clin Invest"},{"key":"380_CR56","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s13679-019-00364-y","volume":"8","author":"GS Christodoulatos","year":"2019","unstructured":"Christodoulatos GS, Spyrou N, Kadillari J, Psallida S, Dalamaga M. The role of adipokines in breast cancer: current evidence and perspectives. Curr Obes Rep. 2019;8:413\u201333. https:\/\/doi.org\/10.1007\/s13679-019-00364-y.","journal-title":"Curr Obes Rep"},{"key":"380_CR57","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s13679-019-00360-2","volume":"8","author":"I Karampela","year":"2019","unstructured":"Karampela I, Christodoulatos GS, Dalamaga M. The role of adipose tissue and adipokines in sepsis: inflammatory and metabolic considerations, and the obesity paradox. Curr Obes Rep. 2019;8:434\u201357. https:\/\/doi.org\/10.1007\/s13679-019-00360-2.","journal-title":"Curr Obes Rep"},{"key":"380_CR58","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cyto.2019.03.002","volume":"119","author":"I Karampela","year":"2019","unstructured":"Karampela I, Christodoulatos GS, Kandri E, Antonakos G, Vogiatzakis E, Dimopoulos G, et al. Circulating eNampt and resistin as a proinflammatory duet predicting independently mortality in critically ill patients with sepsis: a prospective observational study. Cytokine. 2019;119:62\u201370. https:\/\/doi.org\/10.1016\/j.cyto.2019.03.002.","journal-title":"Cytokine"},{"key":"380_CR59","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2217\/bmm.13.99","volume":"8","author":"M Dalamaga","year":"2014","unstructured":"Dalamaga M. Resistin as a biomarker linking obesity and inflammation to cancer: potential clinical perspectives. Biomark Med. 2014;8:107\u201318. https:\/\/doi.org\/10.2217\/bmm.13.99.","journal-title":"Biomark Med"},{"key":"380_CR60","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.maturitas.2008.03.012","volume":"59","author":"G Hroussalas","year":"2008","unstructured":"Hroussalas G, Kassi E, Dalamaga M, Delimaris I, Zachari A, Dionyssiou-Asteriou A. Leptin, soluble leptin receptor, adiponectin and resistin in relation to OGTT in overweight\/obese postmenopausal women. Maturitas. 2008;59:339\u201349. https:\/\/doi.org\/10.1016\/j.maturitas.2008.03.012.","journal-title":"Maturitas"},{"key":"380_CR61","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12020-018-1550-3","volume":"61","author":"T Stratigou","year":"2018","unstructured":"Stratigou T, Dalamaga M, Antonakos G, Marinou I, Vogiatzakis E, Christodoulatos GS, et al. Hyperirisinemia is independently associated with subclinical hypothyroidism: correlations with cardiometabolic biomarkers and risk factors. Endocrine. 2018;61:83\u201393. https:\/\/doi.org\/10.1007\/s12020-018-1550-3.","journal-title":"Endocrine"},{"key":"380_CR62","doi-asserted-by":"publisher","unstructured":"Barrea L, Nappi F, Di Somma C, Savanelli MC, Falco A, Balato A, et al. Environmental risk factors in psoriasis: the point of view of the nutritionist. Int J Environ Res Public Health. 2016;13. https:\/\/doi.org\/10.3390\/ijerph13070743.","DOI":"10.3390\/ijerph13070743"},{"key":"380_CR63","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1111\/jdv.15177","volume":"32","author":"E Dauden","year":"2018","unstructured":"Dauden E, Blasco AJ, Bonanad C, Botella R, Carrascosa JM, Gonzalez-Parra E, et al. Position statement for the management of comorbidities in psoriasis. J Eur Acad Dermatol Venereol. 2018;32:2058\u201373. https:\/\/doi.org\/10.1111\/jdv.15177.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"380_CR64","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheum. 2019;71:5\u201332. https:\/\/doi.org\/10.1002\/art.40726.","journal-title":"Arthritis Rheum"},{"key":"380_CR65","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1080\/14656566.2019.1603294","volume":"20","author":"M Dalamaga","year":"2019","unstructured":"Dalamaga M, Papadavid E. Can we better strategize our choice of pharmacotherapy for patients with co-morbid psoriasis and obesity? Expert Opin Pharmacother. 2019;20:1303\u20138. https:\/\/doi.org\/10.1080\/14656566.2019.1603294.","journal-title":"Expert Opin Pharmacother"},{"key":"380_CR66","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1111\/ijd.14523","volume":"58","author":"A Korovesi","year":"2019","unstructured":"Korovesi A, Dalamaga M, Kotopouli M, Papadavid E. Adherence to the Mediterranean diet is independently associated with psoriasis risk, severity, and quality of life: a cross-sectional observational study. Int J Dermatol. 2019;58:e164\u2013e65. https:\/\/doi.org\/10.1111\/ijd.14523.","journal-title":"Int J Dermatol"},{"key":"380_CR67","doi-asserted-by":"publisher","first-page":"e12810","DOI":"10.1111\/dth.12810","volume":"32","author":"A Molina-Leyva","year":"2019","unstructured":"Molina-Leyva A, Cuenca-Barrales C, Vega-Castillo JJ, Ruiz-Carrascosa JC, Ruiz-Villaverde R. Adherence to Mediterranean diet in Spanish patients with psoriasis: cardiovascular benefits? Dermatol Ther. 2019;32:e12810. https:\/\/doi.org\/10.1111\/dth.12810.","journal-title":"Dermatol Ther"},{"key":"380_CR68","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1001\/jamadermatol.2018.2127","volume":"154","author":"C Phan","year":"2018","unstructured":"Phan C, Touvier M, Kesse-Guyot E, Adjibade M, Hercberg S, Wolkenstein P, et al. Association between Mediterranean anti-inflammatory dietary profile and severity of psoriasis: results from the NutriNet-Sante cohort. JAMA Dermatol. 2018;154:1017\u201324. https:\/\/doi.org\/10.1001\/jamadermatol.2018.2127.","journal-title":"JAMA Dermatol"},{"key":"380_CR69","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12967-014-0372-1","volume":"13","author":"L Barrea","year":"2015","unstructured":"Barrea L, Balato N, Di Somma C, Macchia PE, Napolitano M, Savanelli MC, et al. Nutrition and psoriasis: is there any association between the severity of the disease and adherence to the Mediterranean diet? J Transl Med. 2015;13:18. https:\/\/doi.org\/10.1186\/s12967-014-0372-1.","journal-title":"J Transl Med"},{"key":"380_CR70","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/j.1365-2133.2012.11211.x","volume":"168","author":"EW Hossler","year":"2013","unstructured":"Hossler EW, Wood GC, Still CD, Mowad CM, Maroon MS. The effect of weight loss surgery on the severity of psoriasis. Br J Dermatol. 2013;168:660\u20131. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11211.x.","journal-title":"Br J Dermatol"},{"issue":"Suppl 1","key":"380_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0001-7310(12)70001-7","volume":"103","author":"E Dauden","year":"2012","unstructured":"Dauden E, Castaneda S, Suarez C, Garcia-Campayo J, Blasco AJ, Aguilar MD, et al. Integrated approach to comorbidity in patients with psoriasis.Working Group on Psoriasis-associated Comorbidities. Actas Dermosifiliogr. 2012;103(Suppl 1):1\u201364. https:\/\/doi.org\/10.1016\/s0001-7310(12)70001-7.","journal-title":"Actas Dermosifiliogr"},{"key":"380_CR72","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/jdv.12024","volume":"27","author":"E Dauden","year":"2013","unstructured":"Dauden E, Castaneda S, Suarez C, Garcia-Campayo J, Blasco AJ, Aguilar MD, et al. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J Eur Acad Dermatol Venereol. 2013;27:1387\u2013404. https:\/\/doi.org\/10.1111\/jdv.12024.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"380_CR73","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/jdv.13354","volume":"29","author":"A Nast","year":"2015","unstructured":"Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris--update 2015--short version--EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29:2277\u201394. https:\/\/doi.org\/10.1111\/jdv.13354.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"380_CR74","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2147\/ccid.s44843","volume":"7","author":"C Ni","year":"2014","unstructured":"Ni C, Chiu MW. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol. 2014;7:119\u201332. https:\/\/doi.org\/10.2147\/ccid.s44843.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"380_CR75","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80:27\u201340. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.057.","journal-title":"J Am Acad Dermatol"},{"key":"380_CR76","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.jhep.2007.01.024","volume":"46","author":"P Rosenberg","year":"2007","unstructured":"Rosenberg P, Urwitz H, Johannesson A, Ros AM, Lindholm J, Kinnman N, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol. 2007;46:1111\u20138. https:\/\/doi.org\/10.1016\/j.jhep.2007.01.024.","journal-title":"J Hepatol"},{"key":"380_CR77","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1468-3083.2007.02429.x","volume":"22","author":"P Gisondi","year":"2008","unstructured":"Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol. 2008;22:341\u20134. https:\/\/doi.org\/10.1111\/j.1468-3083.2007.02429.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"380_CR78","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/jcph.1063","volume":"58","author":"Z Yao","year":"2018","unstructured":"Yao Z, Hu C, Zhu Y, Xu Z, Randazzo B, Wasfi Y, et al. Population pharmacokinetic modeling of guselkumab, a human IgG1lambda monoclonal antibody targeting IL-23, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2018;58:613\u201327. https:\/\/doi.org\/10.1002\/jcph.1063.","journal-title":"J Clin Pharmacol"},{"key":"380_CR79","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/bjd.12110","volume":"168","author":"KA Papp","year":"2013","unstructured":"Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168:412\u201321. https:\/\/doi.org\/10.1111\/bjd.12110.","journal-title":"Br J Dermatol"},{"key":"380_CR80","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80:43\u201353. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.056.","journal-title":"J Am Acad Dermatol"},{"key":"380_CR81","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jid.2017.07.065","volume":"137","author":"AG Ellis","year":"2017","unstructured":"Ellis AG, Flohr C, Drucker AM, Network meta-analyses of systemic treatments for psoriasis: a critical appraisal: Original Articles, Jabbar-Lopez ZK, Yiu ZZN, et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol. 2017;137:1646\u201354.","journal-title":"J Invest Dermatol"},{"key":"380_CR82","doi-asserted-by":"publisher","first-page":"CD011535","DOI":"10.1111\/bjd.17335","volume":"12","author":"E Sbidian","year":"2017","unstructured":"Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017;12:CD011535. Br J Dermatol 2019;180:282\u201388. https:\/\/doi.org\/10.1111\/bjd.17335.","journal-title":"Cochrane Database Syst Rev"},{"key":"380_CR83","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.14493","volume":"175","author":"KA Papp","year":"2016","unstructured":"Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175:273\u201386. https:\/\/doi.org\/10.1111\/bjd.14493.","journal-title":"Br J Dermatol"},{"key":"380_CR84","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/jdv.14598","volume":"32","author":"I Vujic","year":"2018","unstructured":"Vujic I, Herman R, Sanlorenzo M, Posch C, Monshi B, Rappersberger K, et al. Apremilast in psoriasis - a prospective real-world study. J Eur Acad Dermatol Venereol. 2018;32:254\u20139. https:\/\/doi.org\/10.1111\/jdv.14598.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"380_CR85","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173:1387\u201399. https:\/\/doi.org\/10.1111\/bjd.14164.","journal-title":"Br J Dermatol"},{"key":"380_CR86","doi-asserted-by":"publisher","unstructured":"Hemoglobin A1c and weight changes with apremilast in patients with psoriasis and psoriatic arthritis: pooled laboratory analysis of the phase 3 ESTEEM and PALACE trials. J Am Acad Dermatol 2018;79:AB151. Doi:https:\/\/doi.org\/10.1016\/j.jaad.2018.05.625.","DOI":"10.1016\/j.jaad.2018.05.625"},{"key":"380_CR87","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000472149","volume":"233","author":"W Ip","year":"2017","unstructured":"Ip W, Kirchhof MG. Glycemic control in the treatment of psoriasis. Dermatology. 2017;233:23\u20139. https:\/\/doi.org\/10.1159\/000472149.","journal-title":"Dermatology"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-020-00380-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-020-00380-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-020-00380-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T19:55:20Z","timestamp":1621108520000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13679-020-00380-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,16]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["380"],"URL":"https:\/\/doi.org\/10.1007\/s13679-020-00380-3","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,16]]},"assertion":[{"value":"16 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Kyriaki Paroutoglou, Evangelia Papadavid, Gerasimos Socrates Christodoulatos, and Maria Dalamaga declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}